MICHAEL BLOCKER: Open Payments
NPI 1487134052 · NAVARRE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$879 in 45 payments from 15 companies in 2025. Trend: 2023 $356 · 2024 $423 · 2025 $879
Food & beverage: $879
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $258 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $107 |
| Corium, LLC | 3 | $92 |
| Amgen Inc. | 4 | $62 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: AIRSUPRA, XIFAXAN, Azstarys, EVENITY, Kerendia, REXULTI, FARXIGA, CAPLYTA.
Industry payments across FL — which companies pay providers there.
